Why One Investor Is Betting on Platform Technologies to Change the World

Episode Summary

Executive Summary: Brian Johnson explains how OS Fund backs “platform” technologies at the atomic, molecular, and organism level to solve major problems faster and cheaper than traditional biotech. He argues biology’s falling costs now make deep-tech companies commercially viable in 1–3 years, with the potential to transform drug discovery, materials, agriculture, climate solutions, and healthcare.

Main Topics: OS Fund’s mission and thesis (Priority: 5/5): Johnson says the fund was created to back hard-science companies building tools that can rewrite the operating systems of life and address major challenges like climate change. Why biology looks more like tech now (Priority: 5/5): He argues the cost and speed of biology have improved dramatically, making life-science startups resemble traditional technology ventures in timeline, capital needs, and risk profile. Platform technologies over single products (Priority: 5/5): The fund prefers broad platforms—tools that can be applied across many use cases—rather than companies built around one molecule or one disease. Examples across synthetic biology, microbiome, and materials (Priority: 4/5): Johnson cites investments in Ginkgo Bioworks, uBiome, Numat, and gene-editing companies as examples of technologies that can reshape manufacturing, health, and chemistry. Commercialization strategy and de-risking (Priority: 4/5): He emphasizes starting with simple, first-to-market products, often after government/non-dilutive funding, to prove viability before tackling more complex applications. Climate change and industrial transformation (Priority: 4/5): Johnson believes the biggest climate impact will come from changing agriculture and manufacturing inputs—fertilizers, petrochemicals, and physical materials—rather than relying only on consumer behavior or policy. Future upside and unexpected applications (Priority: 4/5): He frames these technologies as general-purpose platforms likely to create unforeseen applications, similar to the printing press or internet.

Key Arguments: The most powerful tools for solving global problems operate at the atomic, molecular, and organism level, not at the level visible to the naked eye. Biology has undergone a cost revolution, making it possible to build life-science companies with far less capital and far shorter development timelines than people assume. Platform technologies are more valuable than single products because one core capability can be applied to many markets, increasing scalability and reducing risk. The best investments are entrepreneurs who can commercialize the simplest useful version first, then expand to more complex applications. Climate solutions require changes in manufacturing and agriculture, not just recycling, EVs, or waiting for politicians to act. Synthetic biology can replace environmentally intensive processes, such as growing roses for fragrance or raising livestock for meat. Gene editing, microbiome analysis, and molecular design could lower the cost and increase the speed of diagnostics, therapeutics, and materials development. Acquirers will likely value the platform and iterative capability of these companies, not just the first molecule or product they produce.

Data Points: OS Fund size: $100 million - Johnson says he invested this amount in the fund to rewrite the “operating systems” of the world. First human genome sequencing cost: About $1 billion - He cites the early-2000s cost of sequencing the first human genome as an example of biology’s past expense. Projected genome sequencing cost next year: About $200 - Used to show the dramatic decline in sequencing costs. Typical initial check size: $500,000 - OS Fund can come in as first money at the seed stage. Investment range: $500,000 to $25 million - Johnson describes the fund’s typical check range. Human cells in the body: About 60 trillion cells total - He describes the body as a complex biological system. Bacterial cells in the body: About 30 trillion bacterial cells - He uses this to explain the importance of the microbiome. Human cells in the body (subset): About 30 trillion human cells - Paired with bacterial cells to illustrate the body’s mixed ecosystem. Transport emissions share: 14% of global emissions - He notes transportation is only a portion of the climate problem. Gas storage density improvement: 80 times the density - Numat’s metal-organic framework technology can store gas at much higher density. Gene therapy cost target: From around $1 million to $1,000 - Syntego aims to dramatically reduce the cost of gene therapy. Microbial engineering complexity (example): “1 out of 10” on complexity scale - Johnson says Ginkgo’s early fragrance/flavor work was relatively simple before more complex applications. Protein/photosynthesis efficiency: 50% efficient - He says photosynthesis is only about half efficient because it evolved under ancient Earth conditions.

Pivotal Quotes: "“We need to rewrite the operating systems of the world.”" — Brian Johnson: He explains why OS Fund invests in foundational biological and chemical platforms. "“This is basically 1978 all over again.”" — Brian Johnson: He compares the current biology/engineering moment to the early era of modern computing. "“We invest in entrepreneurs to understand that they can build a core technology platform that can be used for just about anything in the entire world.”" — Brian Johnson: He defines OS Fund’s platform-investing philosophy.

Implications: The interview suggests life sciences is entering a tech-like scaling era, where platform biology could cut costs, accelerate development, and produce major climate and health breakthroughs. Investors and founders should prioritize broad, reusable technologies over narrow one-off products.